Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2012

View Archived Issues

Sangamo cell therapy increases CD4+ T-cell counts in patients with HIV

Novacta Biosystems develops novel candidate antibacterials

Phase I trial assesses interaction between diabetes therapies

Novel first-in-human data presented on Medimmune cancer immunotherapy

New data highlight role of lymphopoietin in chronic rhinosinusitis with nasal polyps

U.S. study links SNPs to complications after subarachnoid hemorrhage

Cartagenia enters partnership for rare epilepsy syndromes

Merck & Co. enters into collaboration to create new institute

Ampio provides update on Optina trial

Once-daily tramadol capsule launched in Canada for chronic pain

Alnylam launches phase I trial of transthyretin-mediated amyloidosis therapy

Provectus Pharmaceuticals reports topline phase II data on PH-10

QRxPharma and Actavis sign new licensing agreement

CUNY to validate diagnostic antibodies

Novel GPR124 receptor agonists designed in U.S.

New potential flu therapies presented

New nicotinic acetylcholine receptor ligands synthesized

Boehringer Ingelheim Pharma divulges new MPGES-1 inhibitors

Santhera reports novel mitochondrial function modulators

Avaxia receives second NIH grant for oral IBD immunotherapeutic

Merck & Co. to discontinue development of vernakalant formulation

AstraZeneca and Targacept give update on TC-5214 development

First once-daily 24-hour LABA for COPD maintenance launched in U.S.

Enrollment complete in phase III trials of allergy immunotherapy

Cellceutix enters collaboration agreement to support Kevetrin development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...